where to now..

Putting the boxing gloves aside regarding ‘the board’. Where does our key asset, ‘XToll’ stand at the moment..

Are we expecting more analysis or trials for the use of Xtoll on RA. Or are we essentially calling it a duster?

Is lupus the market we are going to be chasing now, or was this just a dog/mouse heard in the winds?

Regardless on your take of the current board, the fact is that the overwhelming majority voted them in. In hindsight whether this was a good or bad decision, and whether it went to far as to chase the entire board away is history. In my opinion we have made a choice to go with the elected and they need to start showing some plan sooner rather than later. Do any others feel left a little in the dark?

If so, the monumental question which remains is, what is the future of Xtoll..